Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Triple-Receptor Agonist | Metabolic Research Compound
Retatrutide is among the most advanced metabolic peptides currently under research, theoretically engaging three receptor pathways simultaneously — GLP-1, GIP, and glucagon. Studies suggest it may theoretically reduce appetite and support glucose regulation via GLP-1 activity, enhance insulin sensitivity and metabolic efficiency through GIP engagement, and increase energy expenditure and fat oxidation via glucagon receptor activation. Research interest in this compound has grown substantially given its theoretical multi-pathway approach to metabolic support.
Triple-Receptor Agonist | Metabolic Research Compound
Retatrutide is among the most advanced metabolic peptides currently under research, theoretically engaging three receptor pathways simultaneously — GLP-1, GIP, and glucagon. Studies suggest it may theoretically reduce appetite and support glucose regulation via GLP-1 activity, enhance insulin sensitivity and metabolic efficiency through GIP engagement, and increase energy expenditure and fat oxidation via glucagon receptor activation. Research interest in this compound has grown substantially given its theoretical multi-pathway approach to metabolic support.